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CD8
+ cytotoxic T lymphocytes (CTL) are key determinants of immunity to intracellular
pathogens and neoplastic cells. Recognition of specific antigens in the form of peptide-
MHC class I complexes (pMHCI) presented on the target cell surface is mediated by
T cell receptor (TCR) engagement. The CD8 coreceptor binds to invariant domains of
pMHCI and facilitates antigen recognition. Here, we investigate the biological effects of
a Q115E substitution in the a2 domain of human leukocyte antigen (HLA)-A*0201 that
enhances CD8 binding by *50% without altering TCR/pMHCI interactions. Soluble
and cell surface-expressed forms of Q115E HLA-A*0201 exhibit enhanced recognition
by CTL without loss of specificity. These CD8-enhanced antigens induce greater CD3
f chain phosphorylation in cognate CTL leading to substantial increases in cytokine
production, proliferation and priming of naive T cells. This effect provides a
fundamental new mechanism with which to enhance cellular immunity to specific
T cell antigens.
Introduction
The TCR coreceptor CD8 binds to largely invariant
domains of MHC class I (MHCI) [1] and facilitates the
process of antigen recognition by a number of mechan-
isms[2–4].Todate,it hasbeen establishedthatCD8aids
antigen recognition by recruiting the TCR to specific
membrane domains believed to be privileged sites for
TCR-mediated signal transduction [5], recruiting essen-
tial signalling molecules to the intracellular side of the
TCR/CD3/f complex [6, 7] and stabilising the TCR/
peptide-MHCI complex (pMHCI) interaction at the cell
surface [8, 9]. It is not yet clear whether CD8 has other
roles in antigen recognition.
The role of CD8 has traditionally been examined
using transfected T cell hybridomas or anti-CD8
antibodies. These reagents do not enable discrimination
between the role of the pMHCI/CD8 interaction and
other possible roles of CD8 in antigen recognition such
as direct coupling of CD8 to the TCR [10, 11]. MHCI
mutations that reduce or abrogate the pMHCI/CD8
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have enabled the study of this interaction in isolation.
The Tcell coreceptors CD8 and CD4 playa unique role in
biology by assisting in the recognition of pMHCI and
pMHCII antigens, respectively, without altering the
specificity of TCR/pMHC interactions. This role is
facilitated by the uniquely low affinities of the
pMHCI/CD8 and pMHCII/CD4 interactions. Human
CD8andCD4bindtotheirrespectivepMHCligandswith
KD >100 lM and represent the very weakest 1:1
molecular interactions at the cell surface to which a
biological function can be attributed [16].
Previous studies have compared the recognition of
antigen in the presence or absence of wild-type pMHCI/
CD8 interactions [6,12–15,17–20]. In addition, a recent
study has examined the normalisation of the non-
canonical HLA-A*6801 CD8 binding domain [21].
However, the biological effects of supranormal CD8
binding have not been examined before. Here, we
undertake the first study of the biological effects of
increasing the affinity of the pMHCI/CD8 interaction
using mutations that enhance CD8 binding while TCR/
pMHCI interactions remain faithful.
Results
Enhancement of the HLA-A2/CD8 interaction
We have recently characterized a series of mutations in
the CD8 binding domain of HLA-A*0201 (HLA-A2 from
hereon) that alter the binding of CD8aa, determined by
surface plasmon resonance (SPR), without changing the
interaction with HLA-A2-restricted TCR. The CD8
interaction with pMHCI is dominated by CD8a [22].
CD8aa and CD8ab bind to pMHCI with similar affinities
[23, 24]. Mathematical modeling predicts a linear
relationship between the monomeric affinity of the
HLA-A2/CD8 interaction and TCR/pMHCI off rate.
Consistent with this, we observe a linear relationship
between the monomeric affinity of HLA-A2/CD8aa
binding determined by SPR and TCR/pMHCI off rate on
the cell surface of CTL which express CD8ab. This
suggests that our MHCI mutated molecules bind to
human CD8aa and CD8ab with similar affinities [9].
We have further used a range of biophysically
characterized altered peptide ligands to show that the
about two-fold stabilisation of TCR/pMHCI interactions
afforded by CD8 binding [9] remains constant over the
entirerangeofTCR/pMHCIinteractionsthatweareable
to study at the cell surface in the absence of CD8 binding
(KD 2–40 lM) (Laugel et al., unpublished). Molecular
dynamics studies predicted that a Q115-to-E (Q115E)
mutation in the a2 domain of HLA-A2 would shorten a
key hydrogen bond and enhance CD8 binding (Fig. 1).
SPR studies confirmed that Q115E HLA-A2 exhibited
enhanced CD8 binding without affecting the binding of
cognate TCR [9]. Thus, the Q115E mutation generates
HLA-A2 molecules for which CD8 interaction is
enhanced by *50% (KD *85 lM as compared to
KD *130 lM for the wild-type interaction) [9]. Here,
for the first time, we examine the biological conse-
quences of enhanced CD8 binding using this MHCI
mutation.
CD8 enhancement results in improved antigen
recognition at the cell surface
Antigenic peptide presented in the context of Q115E
HLA-A2 is recognized substantially better than in the
context of wild-type HLA-A2 (Fig. 2). We recently used
the series of HLA-A2 molecules mentioned above that
vary in their CD8 binding by >1000-fold while retaining
faithful interactions with HLA-A2-specific TCR to model
the contribution that CD8 makes to TCR/pMHCI
stabilisation at the cell surface [9]. These data show
that the increased affinity for CD8 afforded by the
Q115E substitution in HLA-A2 extends the mean
duration of the TCR/pMHCI interaction by only <2%
[9]. This small enhancement of TCR/pMHCI stability
would, by itself, not be expected to improve CTL
activation by target cells to the levels observed in a
Figure 1. The CD8a1R 4 guanidinium moiety forms a stronger
electrostatic interaction with the HLA-A*0201 Q115E mutant
carboxylate than with the wild-type Q residue. HLA-A2 heavy
chain is shown in yellow complexed with b2m (red) and CD8
(green). The inset shows the location of the key residues Q115 in
HLA-A2 and R4 in CD8a1. For clarity, the right-hand-side close
up is rotated about the vertical relative to the standard view.
The wild-type Q115 residue is shown for comparison (yellow).
The Q115/R4 Oe1..Ng1 distance in the HLA-A2 CD8aa crystal
structure [1] is 3.18  . This distance is predicted by the
molecular dynamics simulation to shorten to an average of
2.56   with Q115E (shown as broken line) and enables these
moieties to form a strong electrostatic interaction.
Linda Wooldridge et al. Eur. J. Immunol. 2007. 37: 1323–1333 1324
f 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.euvariety of functional recognition assays (Fig. 2). These
findings strongly suggest that stabilisation of the TCR/
pMHCI interaction is not the sole, and indeed not the
major, mechanism through which the CD8 coreceptor
enhances ligand recognition.
Antigen presented in the context of Q115E HLA-A2
was shown to be better at inducing IFN-c and MIP-1b
production from a total of 14 different CTL clones
specific for seven different antigens (Fig. 2A, B and data
not shown). Q115E HLA-A2-expressing cells were also
found to be superior targets in a CTL lysis assay (Fig. 3).
Notably, antigen-presenting cells (APC) bearing peptide
antigen in the context of Q115E HLA-A2 were able to
induce substantially better proliferation of tumour-
specific CTL clones specific for several different epitopes
(Fig. 2C, D and data not shown).
We excluded the possibility that these differences
were due to small differences in HLA-A2 density on the
APC surface by examining multiple C1R-A2 clones with
identical levels of HLA-A2 surface expression as
Figure 2. CTL antigen sensitivity and effector function are enhanced by a small increase in the HLA-A2/CD8 interaction. (A)
Number of spots produced in IFN-c ELISPOT with EBV-, tyrosinase- or telomerase-specific HLA-A2-restricted CTL clones in
response to peptide-pulsed C1R target cells expressing wild-type HLA-A2, DT227/8KA HLA-A2, or Q115E HLA-A2. Assays were
performed with 2.510
2 CTL and 2.510
4 C1R transfectants at 37
C for 4 h. (B) MIP-1b production by a panel of HIV-1 Gag-specific
HLA-A2-restricted CTL clones in response to the above-mentioned C1R targets. CTL (2.510
4) were incubated with 2.510
4 C1R
transfectants at 37
C for 4 h. Supernatant was assayed by chemokine ELISA as previously described [44]. (C, D) Proliferation of the
CFSE-labelled anti-tumour CTL clones 1C2 (C) and ILA1 (D), specific for the HLA-A2-restricted telomerase-derived epitopes
RLVDDFLLV and ILAKFLHWL, respectively, stimulated with the indicated C1R targets pulsed with 1 lM cognate peptide.
Proliferation results over 6 days are indicated by progressive dilution of cellular CSFE content; each division can be visualized
incrementally and quantified as a percentage of the total population as depicted.
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clonal antibody (BB7.2) (Fig. 4C). In addition, we
manufactured GFP fusion vectors of all the HLA-A2
mutants used in this study (Fig. 4B). These targets
express identical levels of GFP by flow cytometry
(Fig. 4D) and fluorescence microscopy confirmed that
the vast majority of this protein is associated with the
cytoplasmic membrane (data not shown). Target cells
expressing C1R-A2 or C1R-GFP-A2 gave similar results
in functional T cell assays and clearly demonstrate that
the Q115E mutation in HLA-A2 results in substantial
improvements in antigen recognition by cognate CTL.
An incremental increase in HLA-A2/CD8 affinity
enhances CTL priming
Thymic output in healthy HLA-A2
+ individuals is known
to generate a high frequency of naive CD8
+ T cells that
can recognize the self antigen Melan A/MART1 [25].
This system represents the only known naive self-
peptide-specific T cell repertoire directly accessible in
humans [25]. We have previously examined the priming
of naive CTL directly ex vivo [26]. Here, we used this
system to show that antigen presented in the context of
Q115E-substituted HLA-A2 can prime substantially
more Melan A tetramer
+ CD8
+ cells from HLA-A2
+
peripheral blood mononuclear cells (PBMC) than wild-
type antigen (Fig. 5). Similar results were observed with
HLA-A2
+ PBMC from four other individuals in six
separate experiments (data not shown). Cells bearing
antigen in the context of CD8-null (DT227/8KA)
HLA-A2 consistently primed far fewer CTL than targets
bearing wild-type antigen. In four of six experiments,
CD8-null targets failed to prime any Melan A-specific
CTL at all (data not shown).
Peptide-pulsed wild-type HLA-A2 target cells in-
duced a tetramer
+ population with a heterogeneous
staining pattern that could be arbitrarily split into
tetramer
high and tetramer
low populations previously
shown to correspond to high- and low-avidity CTL,
respectively [27]. In donors where CD8-null targets
were able to prime Melan A-specific CTL, it is notable
that only tetramer
high CTL emerged (Fig. 5). This is
consistent with a recent study [28] that used mice
transgenic for HLA-A2, which does not bind to murine
CD8 [6], to generate high-affinity TCR specific for an
epitope from p53. Importantly, Q115E HLA-A2 targets
not only induced three to five times more Melan A-
specific CTL than wild-type HLA-A2 targets but also
primed a large proportion of tetramer
high CTL. High-
avidity CTL are thought to be optimal for adoptive CTL
transfer therapy as they have a proven ability to control
tumour growth in vivo. Tools such as Q115E HLA-A2
target cells that have the potential to expand CTL with a
high avidity for pMHCI from PBMC could therefore
facilitate the development of adoptive CTL transfer
therapies.
An incremental increase in HLA-A2/CD8 affinity
induces better f chain phosphorylation
To investigate the mechanisms underlying the enhanced
antigenicity of Q115E-substituted antigens, we exam-
ined the early intracellular signalling events induced by
wild-type and CD8-enhanced (Q115E) HLA-A2 ligands
and compared this to CD8-null (DT227/8KA) ligands.
CD8-enhanced HLA-A2 induced identical levels of
tyrosine phosphorylation to wild-type HLA-A2 for most
proteins (Fig. 6A) with one notable exception. C1R
targets bearing Q115E HLA-A2 were abletoinduce more
of the fully phosphorylated p23 form [29] of the TCR
f chain in anti-tumour and anti-viral CTL compared to
similar targets bearing wild-type HLA-A2 standardized
for surface antigen expression levels (Fig. 6A, B). This
suggests that the improved antigenicity of CD8-en-
hanced antigen may be afforded by an increased ability
of CD8-associated p56
lck to phosphorylate the cytoplas-
mic immunoreceptor tyrosine activation motifs (ITAM)
of the TCR/CD3 complex.
It is curious that we did not observe increased
tyrosine phosphorylation of other proteins thought tobe
further down the TCR-mediated signal transduction
cascade, such as ZAP70, with CD8-enhanced antigen.
This suggests that the phosphorylation of these down-
stream proteins may not require full phosphorylation of
large amounts of the TCR f chain. However, we cannot
exclude the possibility that there are differences at other
Figure 3. A small enhancement in the HLA-A2/CD8 interaction
significantly improves CTL-mediated lysis. C1R cells expres-
sing identical levels of GFP-DT227/8KA HLA-A2, GFP-wild-type
HLA-A2 or GFP-Q115E HLA-A2 (Fig. 4) were pulsed for 1 h with
1 lM SLYNTVATL peptide (A) or 1 lM RLVDDFLLV peptide (B).
C1R target cells (1.510
4) were incubated with 310
4 cognate
CTL in a 96-well U-bottomed plate for 2 h. Specific lysis was
calculated by counting CIR-GFP-A2 cells using flow cytometry.
Background lysis in the absence of peptide was near zero at a
2:1 E:Tratio. The error barsindicatethe standard error from the
mean of two replicate experiments.
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enhanced recognition of Q115E antigens may be
channelled through non-protein tyrosine kinase events
downstream of f chain phosphorylation.
Incremental CD8 enhancement does not affect
T cell specificity substantially
Importantly, a small increase in the affinity of the
pMHCI/CD8 interaction did not result in significant loss
of antigen specificity. Enhanced recognition of Q115E-
substituted HLA-A2 extends to weak agonist ligands but
does not result in enhanced recognition of weaker
ligands such as antagonist and null peptides that are
known to have a significantly shorter TCR/pMHC mean
dwell time [30–32] (Fig. 7). We have previously
determined that the 3F/5A variant of the HIV-1 Gag-
derived epitope SLYNTVATL (residues 77–85) acts as a
strict antagonist of 868 CTL [33] in that it disrupts
agonist-induced TCR-mediated signal transduction [6]
without itself inducing functional responses. Ligands
thatact inthis manner are believedtohaveshorter TCR/
pMHC mean dwell times [34, 35]. Q115E-substituted
HLA-A2 was able to augment responses to agonist and
Figure 4. HLA-A2 and GFP-HLA-A2 vectors used in this study and cell surface expression of HLA-A2. (A) HLA-A2 and HLA-A2
mutants were expressed as full-length molecules in pCDNA3.1 (Invitrogen) under G418 (Neo) selection. (B) HLA-A2-GFP fusion
constructs were expressed in pGFP-N2 (Perkin Elmer) under Zeo selection. Vectors were linearized by cutting with BglII or PvuII
(highlighted) prior to transfection. (C) C1R cells were transfected with wild-type HLA-A2, DT227/8KA HLA-A2 or Q115E HLA-A2;
vectorsareshownin(A).TransfectantsweregrownupfromsingleclonesandcloneswithsimilarexpressionlevelsofHLA-A2were
selected. Cells (2.510
5) in 100 lL of FACS buffer were stained with 2.5 lL of the HLA-A2-specific antibody BB7.2 conjugated with
FITC (Serotec) for 20 min, washed twice in FACS buffer and analysed on a FACSCalibur (BD Biosciences). Bars show average mean
fluorescence intensity of two experiments performed 2 wk apart. (D) C1R targets were transfected with HLA-A2-GFP fusion
constructs in the vector shown in (B) and cloned by limiting dilution. Clones were analysed for GFP expression by FACS. Mean
fluorescence is shown for clones used as targets in activation assays.
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ligand into an agonist (Fig. 7 and data not shown).
The pattern of enhancement in ligand recognitionwe
observe is in agreement with studies examining the role
oftheCD4coreceptor[31,32].Thus,ourdatafitwiththe
'sequential engagement' model of TCR/coreceptor
operation, in which the coreceptor acts as a molecular
timerandisonlyabletocontributetoligandrecognitionif
the TCR/pMHCI interaction is of sufficient duration [31,
32]. Fluorescence resonance energy transfer experi-
ments lend some credence to this hypothesis by showing
that agonist, but not antagonist, ligands trigger inter-
molecular interaction between CD4 and the TCR [36].
Enhanced recognition of Q115E-substituted
HLA-A2 antigens extends to soluble molecules
Finally, we examined whether increased recognition of
CD8-enhanced antigens could extend to soluble ligands.
Tetrameric pMHCI complexes have revolutionized the
study of antigen-specific T cells [37, 38] and have been
used to study the activation requirements of CTL
without the need for an APC [6, 39]. Tetramerized
Q115E-substituted HLA-A2 bound to cell surface TCR of
cognate CTL with similar affinity to wild-type HLA-A2
tetramers when analysed following a 30-min incubation
(Fig. 8, 9, [9] and data notshown). Despitethe identical
cross-linking properties that were observed at 30 min,
tetrameric forms of Q115E-substituted HLA-A2 elicited
IFN-c and MIP-1b secretion from cognate CTL in greater
quantities and in response to lower concentrations of
soluble antigen compared towild-type HLA-A2 4 h post-
stimulation (Fig. 8A, B). This increased activation
applied to only those CTL bearing a cognate TCR
(Fig. 8C). Similar results were obtained for the anti-
HIV-1 Gag CTL clone 003 (Fig. 9A, B). Interestingly,
HLAQ115E-substitutedreagentsinduced better tyrosine
phosphorylation of the TCR f chain (Fig. 9C). Thus, as
for cell surface-presented antigen (Fig. 6), the increased
immunogenicity of Q115E-substituted HLA-A2 in solu-
ble form appears to be the result of enhanced early CD8-
mediated signal transduction (Fig. 9)
Figure6.EnhancingthepMHCI/CD8interactionincreasesearly
TCR f chain phosphorylation. One million HLA-A2-restricted,
telomerase-specific CTL of clone ILA1 (A) and 210
6 HLA-A2-
restricted HIV-1 Gag-specific CTL of clone 868 [33] (B) were
exposed to peptide-pulsed C1R targets bearing the indicated
HLA-A2 molecules for 10 min at an E:T ratio of 10:1. Cell
extracts were run by SDS-PAGE and blotted with anti-
phosphotyrosine antibody as described previously [18]. (A)
An entire blot is shown. (B) Detail of partially phosphorylated
f21 andfully phosphoylatedf23. Chemiluminescentsignalwas
collected with a Bio-Rad Fluor-S
TM Multimager. Retardation
factor (Rf) is shown vs. chemiluminescent intensity for
proteins in the 20–24 kD range; a digital image of the
corresponding blot is shown inset, with a key to line traces.
Figure 5. An incremental increase in HLA-A2/CD8 affinity
enhances CTL priming. Fresh HLA-A2
+ human PBMC (10
6) were
incubated with peptide-pulsed, irradiated C1R cells as indi-
cated at an E:T ratio of 5:1. Melan A tetramer
+ CD8
+ cells were
not detected at day 0 (data not shown). Plots show live cells
staining with tetramer and anti-CD8 antibody on day 10 post-
priming. Similar results were obtained with the PBMC from
four other HLA-A2
+ individuals in a total of six experiments
(data not shown). Targets expressing Q115E HLA-A2 consis-
tently 'primed' three to five times more Melan A-specific CTL
than targets expressing wild-type HLA-A2. Targets expressing
DT227/8KA HLA-A2 only primed Melan A-specific CTL as
shown above in two of six experiments.
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Recent studies of murine TCR with variable affinity in
the presence or absence of CD8 indicate that, in order to
elicit CTL activation, virtually all normal syngeneic
interactions require this coreceptor [17]. Furthermore,
CD8 is essential for formation of the immunological
synapse, a requirement that cannot be overcome by
increasing antigen concentration [40]. Thus, CD8 plays
an essential role in the physiological recognition of
MHCI-restricted peptide antigens by CTL. This role for
CD8 is mediated through at least three mechanisms: (1)
stabilisation of the TCR/pMHCI interaction at the cell
surface by approximately two-fold [9]; (2) topograph-
ical organization of cell surface TCR [5]; and (3)
recruitment of intracellular signalling molecules to the
cytoplasmicsideof theTCR/CD3/fcomplex.Mostof the
CD8-mediated benefits in antigen recognition are
removed by DT227/8KA substitution of HLA-A2 [6],
suggesting that the role of the human pMHCI/CD8
interaction might be more significant than the effects of
direct TCR/CD8 interaction. Our previous findings
indicate that the binding energy provided by the
external pMHCI/CD8 interaction is subordinate to other
roles of this interaction in TCR-mediated signal
transduction [18].
The findings of this study pose a number of
interesting dilemmas. First, if slightly improving the
pMHCI/CD8 interaction can enhance the recognition of
peptide antigens, then why has the human immune
system not evolved to incorporatethis feature? Evidence
that different human classical MHCI molecules differ in
their affinity for CD8 further compounds the problem
[41]. Second, within a given CTL clone, we observe a
distinctly non-linear relationship between the 3D
affinity of the pMHCI/CD8 interaction and its biological
role in antigen recognition. It is perplexing that the five-
fold reduction in CD8 binding afforded by the A245V
substitution can have a minimal negative effect on
antigen recognition [18] while a 50% increase in
binding confers such a positive effect.
The answer to both these dilemmas may lie in the
importance of the kinetics of pMHCI/CD8 binding when
compared to TCR/pMHCI interactions as set by thymic
selection. The relationship between 3D affinity and the
functional consequences of two-dimensional, mem-
brane-constrained, interactions at the lymphocyte cell
surface is known to be complex [42] and is not well
understood. These complexities may be further en-
hanced for CD8 [18] which is known to have several
distinctrolesinTcellactivation[2–4].Here,wefindthat
these intricacies are open to subtle exploitation by
showing that even a small increase in the interaction
between human pMHCI and CD8 can result in a
substantial improvement in the recognition of MHCI-
restricted antigen by cognate CTL. The enhancement of
CD8 binding conferred by the Q115E substitution in
HLA-A2 results in only a minor difference in TCR/
pMHCI off rate and half-life at the cell surface [9] and
does not result in significant loss of antigen specificity
(Fig. 7).
Human TCR often bind to cognate pMHCI with
10–100-fold higher affinities than human CD8. Murine
CD8 binds to murine pMHCI with a substantially higher
affinity than the equivalent human interaction [6], such
that CD8 might make a more significant contribution to
Figure 7. Increasing the pMHCI/CD8 interaction does not affect
the specificityof CTL recognition when peptide is presented on
the cell surface. HIV-1 Gag-specific CTL (10
3) of line 868 were
incubated with C1R target cells expressing wild-type HLA-A2,
DT227/8KA HLA-A2, or Q115E HLA-A2 bearing naturally
occurring variants of the SLYNTVATL peptide [33] in an IFN-c
ELISPOT assay [18]. In all conditions of activation, 25% of
line 868 were tetramer
+. Results are plotted as % of tetramer
+
cells producing a spot in the assay. The SLFNAVATL peptide
acts as a strict antagonist of these cells [33, 45].
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system. Enhancing the already over four-fold stronger
murine pMHCI/CD8 interaction still further might lead
to a significant loss in antigen specificity. This appears to
be the case when we super-enhance HLA-A2/CD8
interactions (KD *10 lM) (Laugel et al. and Wool-
dridge et al., manuscripts in preparation). Such
enhancements bring the pMHCI/CD8 interaction into
an affinity range that might allow the initiation of
biological effects in its own right [42]. Thus, our
findings will be difficult to study directly in vivo with
murine models.
We have shown that Q115E substitution of HLA-A2,
which increases the affinity for CD8 from KD *130 lM
to KD *85 lM without altering interactions with the
TCR [9], affords enhanced biological recognition of
Figure 8. SolublepMHCI tetramerswith increased affinity for CD8 enhance CTL activation. (A, B) 10
5 HLA-A2-restricted HIV-1 Gag-
specific CTL of clones 5C11 and 5C3 (A), or HLA-A2-restricted EBV-specific CTL of clone EBV-5 (B), were stained with 1 lg of either
wild-type HLA-A2 or Q115E HLA-A2 tetramer bearing the relevant cognate peptides for 30 min at 37
Ci n2 0lL PBS. For functional
activation assays, (A) 2.510
4 5C11 or 5C3 cells were incubated with either HLA-A2-SLYNTVATL or Q115E HLA-A2-SLYNTVATL
tetramer at the concentrations indicated for 4 h at 37
C, and supernatant was assayed for MIP-1b; (B) 210
3 HLA-A2-restricted
EBV-specific CTL were incubated with either HLA-A2-GLCTLVAML or Q115E HLA-A2-GLCTLVAML tetramer for 4 h in an IFN-c
ELISPOT assay. Staining profiles with each tetramer are shown for comparison in the left panel. (C) HLA-A2 HTLV-1 Tax11–19-
specific CTL (clone D1; 2.510
4) or HLA-A2-restricted HIV-1 p17 Gag-specific CTL (clone 003; 2.510
4) were incubated with
tetramers as shown at 1 lg/mL overnight at 37
C. Supernatant was assayed for MIP-1b by ELISA as described previously [44].
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antigen specificities. We have recently demonstrated
that the Q115E substitution affords a <2% decrease in
TCR/pMHCI disscociation at the cell when compared to
wild-type MHCI [9]. In addition, we have also demon-
strated that the pMHCI/CD8 interaction can act to
enhance the TCR/pMHCI association rate at the cell
surface (Van den Berg et al., submitted). This is
consistent with the findings of a recent publication
[43]. The kinetic advantage afforded by the Q115E
mutation in terms of TCR/pMHCI binding is likely to
enhance antigenicity per se. However, we have pre-
viously demonstrated that the dominant role of the
pMHCI/CD8 interaction is in the recruitment of
signaling molecules to the TCR/CD3 complex and not
the binding energy that it provides; therefore, this
difference is unlikely to account for the extent of the
enhancement we observe.
Indeed, most of the improvements in antigenicity
with Q115E-substituted MHCI appear to be the result of
enhanced early intracellular signal transduction. The
molecular mechanisms that underlie the observed
enhanced early signal transduction are likely to be
complicated as they may be due to either (1) more
efficient signalling molecule recruitment to the TCR/
CD3 complex or (2) more efficient recruitment of TCR/
pMHCI complexes to lipid rafts or other roles of CD8.
Importantly, enhancement of CD8 binding appears to
augment the recognition of agonist and weak agonist
ligands without leading to recognition of ligands with a
shorter TCR/pMHCI interaction. Furthermore, CD8
enhancement can be engineered into any human MHCI
molecule and, therefore, any MHCI-restricted antigen.
CD8-enhanced pMHCI ligands are recognized at lower
concentrations, induce significantly more cytokine
production, enhance CTL proliferation and are better
at priming human CTL directly ex vivo. These findings
indicate a novel mechanism that could enable boosting
of specific cytotoxic immunity, an approach that might
beespeciallypertinent inthecontextofanti-tumourCTL
responses. In addition, the mutations that we describe
might be useful in the setting of vaccination strategies to
enhance the generation of specific pMHCI-restricted
CTL responses.
Figure 9. Tyrosine phosphorylation of the CD3 f chain is enhanced by increasing the affinity of soluble pMHCI antigen for CD8. (A)
HIV-Gag specific CTL (10
5) of clone 003 were stained in 20 lL of PBS with indicated concentrations of either wild-type HLA-A2-
SLYNTVATL or Q115E HLA-A2-SLYNTVATL tetramer for 30 min at 37
C. (B) HLA-A2-restricted HIV-1 p17 Gag-specific CTL (510
2)
were incubated with indicated cognate tetramers for 4 h in an IFN-c ELISPOTassay. (C) Clone 003 CTL (10
6) were exposed to 10 lg/
mLofindicatedcognateHLA-A2tetramerfor3 minandcellextractswererunbySDS-PAGEandblottedwithanti-phosphotyrosine
antibody as described previously [18]. Retardation factor (Rf) is shown vs. chemiluminescent intensity for proteins in the 20–24 kD
range; a digital image of the corresponding blot is shown inset as for Fig. 6B.
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MHCI transfectants and manufacture of target cells
Mutations in HLA-A2 and the biophysical validation of their
effects are published elsewhere [9, 18]. Cells transfected with
HLA-A2 and mutants thereof were produced as described
previously [6]. In each case, cells were cloned and tested with
relevant antibodies to ensure that they expressed identical
levels of MHCI on their surface. The GFP-HLA-A2 fusion
vectors were made as described in Fig. 4.
CTL priming
C1R-A2 cells were pulsed with 1 lM Melan A26–35 (ELAGI-
GILTV) peptide for 90 min, irradiated and washed once in
RPMI 1640 medium. Pulsed irradiated C1R-A2 cells (210
5)
were incubated with 10
6 fresh HLA-A2
+ human PBMC in
RPMI 1640 supplemented with 10% fetal calf serum, 100 U/
mL penicillin, 100 lg/mL streptomycin and 2 mM glutamine
(Sigma) (R10 medium); 200 U/mL IL-2 was added on day 3.
Melan A-specific cells were quantified on day 10 with wild-
type HLA-A2-ELAGIGILTV tetramer.
CTL proliferation
Clone ILA1, specific for the human telomerase reverse
transcriptase-derived peptide hTERT540–548, and clone IC2,
specific for hTERT865–873, were labelled at 10
6 cells/mL with
5 lM CFSE dye for 8 min at room temperature. Fetal calf
serum was added in excess to stop the reaction. Cells were
washed three times and resuspended in R10 medium. CTL
(0.510
6) were mixed at an E:T ratio of 1:1 with C1R target
cells that had been transfected with the wild-type or the
indicated mutant of HLA-A2 and pulsed with 10
–6 Mo f
hTERT540–548, hTERT865–873 or EBV (negative control) pep-
tides. Cells were incubated at 37
C in R10 medium
supplemented with IL-2 at 50 U/mL final concentration in a
2-mL final volume. Samples were collected on a FACSCalibur
flow cytometer and data were analysed with CellQuest
software (BD Biosciences). A minimum of 10 000 live cells
were analysed per sample.
Surface plasmon resonance, soluble pMHCI and TCR
manufacture, and CTL activation assays
Soluble TCR and pMHCI manufacture, tetramerization and
biophysical studies were performed as previously described
[9]. Preparations of pMHCI tetramer were shown to be >98%
tetrameric (data not shown). CTL culture in IL-2 or IL-15 and
functional bioassays are also described elsewhere [10, 18].
Antiphosphotyrosine immunoblots
Antigen-specific CTL (10
6) were exposed to peptide-pulsed
C1R targets at an E:T ratio of 1:10 for 10 min, or 10 lg/mL
tetramer for 3 min, then lysed on ice for 30 min. The nuclear
fraction was pelleted by centrifugation, the remaining lysate
aspirated, added to an equal volume of SDS loading buffer
(350 mM Tris pH 6.8, 350 mM SDS, 30% glycerol, 600 mM
DTT, 175 lM Bromophenol Blue) and boiled for 6 min.
Samples were then loaded into a 12% SDS-PAGE protein gel
for electrophoresis at 100 V for 16 h. Protein was transferred
from the gel by electrophoresis at 25 V for 50 min. After
blocking for 1 h (1% BSA), the membrane was incubated with
1 lg/mL mouse anti-phosphotyrosine antibody (clone 4G10;
Upstate Biotechnology) for 4 h. After washing, the membrane
was incubated with 0.25 lg/mL sheep anti-mouse peroxidase-
linked secondary antibody (Amersham) in 1% BSA, 2.5% milk
powder for 1.5 h. The blot was washed, then developed using
chemiluminescent substrate Supersignal Pico (Perbio). Data
were collected using a Bio-Rad Fluor-S
TM Multimager.
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